Enteris BioPharma is a clinical stage biopharmaceutical company offering innovative formulation solutions built around its proprietary oral drug delivery technologies. In addition to its formulation development expertise, Enteris BioPharma has a 32,000 square foot GMP facility in Boonton, New Jersey, offering an expanding range of manufacturing and development services.
Enteris BioPharma operates as an independent, wholly-owned subsidiary of SWK Holdings Corporation (SWKH.OB). Since its founding in 2013, Enteris has advanced into the clinic multiple internal and external programs leveraging its Peptelligence® platform. The technology has been developed and proven effective over the last decade to enable the oral delivery of peptide-based therapeutics as well as other molecules with low oral bioavailability.
Enteris BioPharma’s internal clinical product pipeline consists of Ovarest® (oral leuprolide tablet), currently being evaluated in for endometriosis, and Tobrate™ (oral tobramycin tablet) for the treatment of uncomplicated urinary tract infection (uUTI). External market analyses demonstrate projected annual U.S. revenue potential for these two products approximate $1 billion in aggregate. Additionally,
Enteris BioPharma’s oral peptide delivery technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include R-Pharm’s TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ KORSUVA™, a potent peripheral kappa opioid receptor agonist with a primary focus for the treatment of pruritus.
Location: United States, New Jersey, Boonton
Employees: 11-50
Total raised: $15M
Founded date: 2013
Investors 1
Date | Name | Website |
- | SWK Holdin... | swkhold.co... |
Funding Rounds 2
Date | Series | Amount | Investors |
10.12.2021 | - | $5M | - |
11.06.2021 | - | $10M | - |
Mentions in press and media 8
Date | Title | Description | Source |
04.03.2024 | Cara Therapeutics Announces Fourth Quarter and Full Year 202... | –Announced prioritization of clinical programs to focus on late-stage development of oral difelikefa... | einpresswi... |
11.01.2022 | ENTERIS BIOPHARMA LAUNCHES ENHANCED WEBSITE SHOWCASING FULL ... | Boonton, NJ - Enteris BioPharma, Inc., a biotechnology company developing innovative drug products b... | marketscre... |
10.12.2021 | SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Mil... | DALLAS, Dec. 9, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focuse... | marketscre... |
10.12.2021 | SWK : ' Subsidiary, Enteris BioPharma, Receives $5 Million M... | SWK Holdings' Subsidiary, Enteris BioPharma, Receives $5 Million Milestone Payment from Cara Therape... | marketscre... |
11.06.2021 | SWK HOLDINGS CORPORATION SWK : ' Subsidiary, Enteris BioPha... | SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therap... | marketscre... |
11.06.2021 | CARA THERAPEUTICS, INC. Cara Therapeutics : SWK Holdings' S... | DALLAS, June 11, 2021 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focus... | marketscre... |
06.08.2013 | Former Unigene management launches oral drug delivery busine... | Dr. Nozer Mehta, the Chief Scientific Officer and Paul Shields, the vice president of operations, he... | medcitynew... |
- | Former Unigene management launches oral drug delivery busine... | In the wake of Unigene’s move to file for Chapter 7 bankruptcy earlier this year, a new biotechnolog... | medcitynew... |